

PRESS RELEASE

Stockholm 21st of August 2018

BioLamina will scale up production to meet customer expectations in Testa Center, a newly built innovation center supported by GE Healthcare and the Swedish Government.

After a very successful year, the Swedish biotech company, BioLamina AB (Stockholm), takes the next step in their expansion plan. BioLamina will scale up production in the newly built facilities at Testa Center in Uppsala to meet the fast-growing demand from customers both in terms of volume and high-quality products to be used in cellular therapy.

BioLamina develops and produces high quality reagents that support the stem cell research community around the world to grow cells and develop future cell therapies. BioLamina's best-selling product, human recombinant laminin 521 substrate, has proven valuable by solving many therapeutic cell-manufacturing process-related issues, such as low cell quality and yield. Over the past decade, Biolaminin 521 has become a preferred cell culture substrate for both basic research and for researchers and companies developing future cell therapies. The volumes purchased world-wide are increasing significantly each year.

To meet the increasing global demand, BioLamina will, together with GE, expand production capacity in the newly built Testa Center in Uppsala. The new site, partially funded by GE and by the Swedish government, offers high-quality bioprocess expertise and will serve as a hub for innovation in biomanufacturing.

"This collaboration will be very valuable for us in this expansion phase to effectively scale-up our production methods. Accessing skills and equipment through the Testa Center is a huge advantage and we're happy that there are such opportunities in Sweden," says Kristian Tryggvason, CEO of BioLamina. He continues: "I am convinced that our unique and innovative products will not only become globally compatible but now we will also get the capability to gain a leading market position".

For more information, please contact:

BIOLAMINA AB
Kristian Tryggvason, CEO Telephone +46 70 743 2233
E-mail: communications@biolamina.com

Press images: www.biolamina.com/press-room-images



ABOUT BIOLAMINA AB

BioLamina commercializes innovations based on research from the Karl Tryggvason laboratory at Karolinska Institute and Duke-NUS, solving technical problems within culturing of embryonic stem cells and other types of primary cells. Many of the products manufactured and sold by BioLamina are based on human recombinant proteins called laminins. The laminins provide cells with an environment mimicking their natural location in the cell culture dish. Different laminin isoforms are expressed in different tissues in the body, hence many different cell types can thrive on laminins. Laminins and other innovations together solve many of the technical problems in research such as reproducibility and low cell quality and therefore help the development of new cell therapies. BioLamina was founded in 2009.

For more information: www.biolamina.com

